Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference

WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
March 11, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

- First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - - Methylmalonic...
March 04, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
March 01, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference

WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
February 24, 2021 16:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy

- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA...
February 17, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy

– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy – WATERTOWN, Mass. and RESEARCH...
February 16, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference

WATERTOWN, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
January 06, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy

- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8...
January 04, 2021 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference

WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...